Long-term prognosis of probands with Brugada-pattern ST-elevation in leads V1-V3

Shiro Kamakura1, Tohru Ohe, Kiyoshi Nakazawa

  • 1Division of Cardiology, National Cardiovascular Center, Suita, Osaka 565-8565, Japan. kamakura@hsp.ncvc.go.jp

Insights

Patients with Brugada syndrome and non-type 1 ECG have a similar prognosis to those with type 1 ECG. Family history of sudden cardiac death and early repolarization predict poor outcomes in Brugada syndrome patients.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Genetics

Background:

  • Brugada syndrome is a rare genetic disorder that affects the heart's electrical system.
  • ST-elevation patterns on an electrocardiogram (ECG) are used to diagnose Brugada syndrome.
  • The prognostic significance of non-type 1 (saddleback) ST-elevation in Brugada syndrome remains unclear.

Purpose of the Study:

  • To determine the long-term prognosis of patients with Brugada syndrome presenting with non-type 1 ECG.
  • To compare the prognosis of patients with non-type 1 ECG to those with the more common type 1 (coved) Brugada-pattern ECG.

Main Methods:

  • A prospective study followed 330 probands with Brugada-pattern ECG (type 1 or non-type 1).
  • ECG patterns were confirmed using drug provocation tests and multiple recordings.
  • Patients were followed for an average of 48.7 months to assess arrhythmic events and syncope.

Main Results:

  • The long-term prognosis for patients with non-type 1 ECG was similar to that of patients with type 1 ECG.
  • The annual arrhythmic event rate for ventricular fibrillation was 10.2% for type 1 and 10.6% for non-type 1.
  • Family history of sudden cardiac death before age 45 and inferolateral early repolarization were independent predictors of fatal arrhythmic events.

Conclusions:

  • The type of ST-elevation pattern (type 1 vs. non-type 1) does not significantly alter the long-term prognosis in Brugada syndrome.
  • Family history of sudden cardiac death and early repolarization are critical indicators of poor prognosis in Brugada syndrome.
  • Spontaneous type 1 ECG and inducibility of ventricular fibrillation during electrophysiological studies were not reliable prognostic markers.
Abstract

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Dysrhythmias IV: Characteristics of Bradyarrhythmias01:18

Dysrhythmias IV: Characteristics of Bradyarrhythmias

Bradyarrhythmias are cardiac rhythm disorders characterized by a slower-than-normal heart rate, typically defined as fewer than 60 beats per minute. Some of which are discussed here:Sinus BradycardiaSinus bradycardia presents a heart rate lower than 60 beats per minute, with a regular rhythm originating from the SA node. The ECG typically shows normal P waves preceding each QRS complex, a normal PR interval (0.12 to 0.20 seconds), and a normal QRS duration (0.06 to 0.10 seconds).First-Degree AV...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...